- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03948646
Safety and Efficacy Study of Sofpironium Bromide in Subjects With Axillary Hyperhidrosis (BBI-4000-CL-302) (Cardigan II)
A Multicenter, Randomized, Double-Blinded, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of Topically Applied Sofpironium Bromide Gel, 15% in Subjects With Axillary Hyperhidrosis
Hyperhidrosis is a disorder of abnormal excessive sweating. Primary hyperhidrosis (armpits, hands, and feet) affects approximately 4.8% of the US population and is believed to be caused by an overactive cholinergic response of the sweat glands.
Current therapies have limited effectiveness, significant side effects, and can be invasive and costly. Sofpironium bromide (BBI-4000) is a novel soft-drug in development for the topical treatment of hyperhidrosis.
This Phase 3 study will assess the safety and efficacy of sofpironium bromide, 15% gel versus vehicle (2 treatment arms), applied for the treatment of axillary hyperhidrosis.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a multicenter, randomized, double-blind, vehicle-controlled study to evaluate the safety and efficacy of topically applied sofpironium bromide, 15% gel in subjects with axillary hyperhidrosis.
Safety will be assessed through collection of vital signs, adverse events, local skin responses, hematology, serum chemistry laboratory testing and urinalysis.
A maximum of 350 subjects will be randomized to receive either sofpironium bromide gel, 15% or vehicle.
Adverse events, vital signs, and local tolerability assessments will be collected at visits across the study. Urine pregnancy tests will be taken throughout the course of the study for women of child bearing potential. Blood and urine samples will be collected and analyzed for routine hematology, chemistry, and urinalysis parameters at specified visits. Patient-reported outcome assessments will be recorded during the study at predefined time points.
The study will be comprised of a total of 13 scheduled visits to take place over approximately 11 to 15 weeks.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35244
- Cahaba Dermatology Skin & Health Center
-
-
Arizona
-
Glendale, Arizona, United States, 85308
- Advanced Research Associates
-
-
Arkansas
-
North Little Rock, Arkansas, United States, 72117
- Arkansas Research Trials
-
-
California
-
Fountain Valley, California, United States, 92708
- First OC Dermatology
-
-
Colorado
-
Centennial, Colorado, United States, 80111
- CoDerm Research
-
Denver, Colorado, United States, 80210
- Colorado Medical Research Center
-
-
Connecticut
-
Cromwell, Connecticut, United States, 06416
- CCD Research, PLLC
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20037
- The GW Medical Faculty Associates
-
-
Florida
-
Coral Gables, Florida, United States, 33134
- Driven Research, LLC
-
Coral Gables, Florida, United States, 33134
- Florida Academic Dermatology Centers Research & Education, LLC
-
Margate, Florida, United States, 33063
- Gsi Clinical Research
-
Miami, Florida, United States, 33155
- Cordova Research Institute
-
Tampa, Florida, United States, 33609
- MOORE Clinical Research, Inc.
-
-
Georgia
-
Sandy Springs, Georgia, United States, 30328
- Advanced Medical Research PC
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- DeNova Research
-
-
Indiana
-
Evansville, Indiana, United States, 47715
- Qualmedica Research, LLC
-
-
Kansas
-
Wichita, Kansas, United States, 67205
- Heartland Research Asssociates - AMR Company
-
-
Louisiana
-
Baton Rouge, Louisiana, United States, 70809
- DelRicht Research
-
New Orleans, Louisiana, United States, 70130
- Etre, Cosmetic Dermatology and Laser Center
-
New Orleans, Louisiana, United States, 70124
- Lupo Center for Aesthetic and General Dermatology
-
New Orleans, Louisiana, United States, 70116
- DelRicht Research
-
-
Maryland
-
Rockville, Maryland, United States, 20850
- Dermassociates
-
-
Massachusetts
-
Watertown, Massachusetts, United States, 02472
- Bay State Clinical Trials, Inc.
-
-
Michigan
-
Clinton Township, Michigan, United States, 48038
- Michigan Center for Skin Care Research
-
Fort Gratiot, Michigan, United States, 48059
- Hamzavi Dermatology, Inc.
-
-
Missouri
-
Saint Louis, Missouri, United States, 63122
- Saint Louis University, Department of Dermatology
-
-
Nebraska
-
Omaha, Nebraska, United States, 68134
- Meridian Clinical Research, LLC
-
-
Nevada
-
Las Vegas, Nevada, United States, 89148
- Jdr Dermatology Research
-
-
New Jersey
-
East Windsor, New Jersey, United States, 08520
- Psoriasis Treatment Center of Central New Jersey
-
-
New York
-
Rochester, New York, United States, 14623
- SkinSearch of Rochester
-
-
North Carolina
-
Charlotte, North Carolina, United States, 28207
- Dermatology, Laser and Vein Specialists of the Carolinas
-
-
Ohio
-
Dublin, Ohio, United States, 43016
- Aventiv Research Inc.
-
-
Pennsylvania
-
Morrisville, Pennsylvania, United States, 19067
- Yardley Dermatology Associates, PC
-
-
Texas
-
Austin, Texas, United States, 78746
- Westlake Dermatology & Cosmetic Surgery
-
Bellaire, Texas, United States, 77401
- Bellaire Dermatology Associates
-
College Station, Texas, United States, 77845
- J&S Studies, Inc.
-
Dallas, Texas, United States, 75231
- Modern Research Associates
-
Houston, Texas, United States, 77030
- University of Texas Health Science Center at Houston
-
Houston, Texas, United States, 77056
- Suzanne Bruce and Associates, P.A.
-
San Antonio, Texas, United States, 78229
- Dermatology Clinical Research Center of San Antonio
-
Webster, Texas, United States, 77598
- Center for Clinical Studies, LTD.LLP
-
-
Washington
-
Spokane, Washington, United States, 99216
- Valley Dermatology and Skin Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female subject ≥ 9 years of age.
- Diagnosis of primary axillary hyperhidrosis that meets the following criteria: (a) symptoms of hyperhydrosis for at least 6 months' duration, (b) HDSM-Ax of 3 - 4 and (c) a minimum GSP of 50 mg is each axilla with a combined total of at least 150 mg.
- The ability to understand and follow all study-related procedures including study drug administration.
- Sexually active female of childbearing potential (FOCBP)* must agree to periodic pregnancy testing and use a medically acceptable method of contraception while receiving protocol-assigned product.
Exclusion Criteria:
- In the Investigators opinion, any skin or subcutaneous tissue conditions of the axilla(s).
- Prior use of any prohibited medication(s) or procedure(s) within the specified timeframe for the treatment of axillary hyperhidrosis.
- Anticholinergic agents used to treat conditions such as, but not limited to, hyperhidrosis, asthma, incontinence, gastrointestinal cramps, and muscular spasms by any route of administration.
- Use of any cholinergic drug (e.g. bethanechol) within 28 days.
- Known cause of hyperhidrosis or known history of a condition that may cause hyperhidrosis (i.e., hyperhidrosis secondary to any known cause such hyperthyroidism, diabetes mellitus, medications, etc.).
- Subjects with unstable diabetes mellitus or thyroid disease, history of renal or hepatic impairment, malignancy glaucoma, intestinal obstructive or motility disease, obstructive uropathy, myasthenia gravis, BPH, neurological or psychiatric conditions, Sjögren's or Sicca syndrome, or cardiac abnormalities that may alter or exacerbate sweat production by the use of anticholinergics in the investigator's opinion.
- Subjects with known hypersensitivity to glycopyrrolate, anticholinergics, or any of the components of the topical formulation.
- Subject is pregnant, lactating or is planning to become pregnant during the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Active
Sofpironium bromide, 15% gel, once per day
|
Active
|
Placebo Comparator: Vehicle
Vehicle gel, once per day
|
Vehicle gel
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The number of participants with treatment emergent adverse events
Time Frame: Through study completion (6 weeks).
|
Summarized by MedDRA LLT with a 3 point severity scale of mild, moderate and severe
|
Through study completion (6 weeks).
|
Change in Hyperhidrosis Disease Severity Measure-Axillary score
Time Frame: 6 weeks
|
Change in score from baseline to end of treatment of an 11 question patient reported outcome assessment, each question has a 5 point response (range 0 [better] - 4 [worse]).
|
6 weeks
|
Gravimetric sweat production
Time Frame: 6 weeks
|
Change in the measured weight of axillary sweat production from baseline to end of study.
|
6 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Patricia Walker, MD PhD, Botanix Pharmaceuticals
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BBI-4000-CL-302
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Axillary Hyperhidrosis
-
Dr. August Wolff GmbH & Co. KG ArzneimittelTherapeutics, Inc.Not yet recruiting
-
Ulthera, IncCompleted
-
Miramar LabsCompletedAxillary HyperhidrosisCanada
-
Commons Aesthetic Plastic SurgerySound Surgical Technologies, LLC.CompletedAxillary HyperhidrosisUnited States
-
Botanix PharmaceuticalsCompletedAxillary HyperhidrosisUnited States
-
miraDry, Inc.Withdrawn
-
Northwestern UniversityCompletedAxillary HyperhidrosisUnited States
-
Ulthera, IncCompletedAxillary HyperhidrosisGermany
-
United States Naval Medical Center, San DiegoCandela Corp.Unknown
-
Botanix PharmaceuticalsCompletedPrimary Axillary HyperhidrosisUnited States
Clinical Trials on Sofpironium Bromide, 15%
-
Botanix PharmaceuticalsCompletedPrimary Axillary HyperhidrosisUnited States
-
Botanix PharmaceuticalsCompletedPrimary Axillary HyperhidrosisUnited States
-
Botanix PharmaceuticalsCompletedAxillary HyperhidrosisUnited States
-
Mayo ClinicCompleted
-
University Hospital, Strasbourg, FranceCompletedSurgical Intervention | MinorFrance
-
National Cancer Institute (NCI)CompletedHead and Neck Squamous Cell Carcinoma | Recurrent Head and Neck Carcinoma | Recurrent Renal Cell Carcinoma | Recurrent Skin Carcinoma | Stage III Renal Cell Cancer | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Recurrent Non-Small Cell Lung Carcinoma | Stage IIIC Cutaneous Melanoma AJCC v7 | Stage IV... and other conditionsUnited States
-
NEURALIS s.a.Active, not recruitingCovid19Belgium, Hungary, Russian Federation, Poland
-
National Cancer Institute (NCI)Completed
-
Dr. Reddy's Laboratories LimitedCompleted
-
University of ZurichCompleted